SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

While the modest reduction in the primary composite outcome of myocardial infarction, stroke or cardiovascular death in the EMPA-REG Outcomes trial was welcome, the 30–40% reductions in heart failure hospitalisation (HFH) and cardiovascular and all-cause deaths in patients treated with empagliflozin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sattar, Naveed, McLaren, James, Kristensen, Søren L., Preiss, David, McMurray, John J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901113/
https://www.ncbi.nlm.nih.gov/pubmed/27112340
http://dx.doi.org/10.1007/s00125-016-3956-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901113/
https://www.ncbi.nlm.nih.gov/pubmed/27112340
http://dx.doi.org/10.1007/s00125-016-3956-x

Ejemplares similares